Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients.

Natsumi MatsumotoYutaro KubotaHiroo IshidaMasae SekidoRyotaro OhkumaTomoyuki IshiguroYuya HirasawaHirotsugu AriizumiTakuya TsunodaToshikazu IkusueKouji KobayashiAtsushi HisamatsuHirokazu ToshimaKen ShimadaKen-Ichi Fujita

Published in: Cancer chemotherapy and pharmacology (2020)

CES1 variants are not associated with capecitabine pharmacokinetics and toxicity.

Keyphrases

phase ii study
locally advanced
metastatic breast cancer
metastatic colorectal cancer
phase iii
copy number
oxidative stress
open label
rectal cancer
squamous cell carcinoma
clinical trial
randomized controlled trial
oxide nanoparticles
genome wide